Ascendis wins FDA approval for achondroplasia drug, waits on EU action

The FDA on Friday approved Ascendis Pharma’s once-weekly treatment for achondroplasia, a form of dwarfism, setting up what could become a three-way competition among drugmakers. The drug, known as navepegritide or TransCon CNP, will be ...